Daily close, T-120 (12/25/24) through T+5. Run-up high $8.49 on 2/27/25, low $4.26 on 4/14/25 (T-120 to T-1). FDA decision 6/11/25. Historical price action, not a forecast.
Positioning before the decision
On May 28, 2025, 14 days before the decision date, at-the-money options priced a move of ±18.3% through Jun 20, 2025 (the first listed expiry after the decision; ATM implied volatility 80%). The stock closed +4.9% at the first close across the decision and -7.0% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Decision facts
FDA decision date2025-06-11
DrugMAVYRET (glecaprevir/pibrentasvir)
IndicationAdults and pediatric patients 3 years and older with acute or chronic hepatitis C virus (H
Was MAVYRET (glecaprevir/pibrentasvir) approved by the FDA?
Yes. The FDA approved the application for MAVYRET (glecaprevir/pibrentasvir) on June 11, 2025. The primary source is linked on this page.
What was MAVYRET (glecaprevir/pibrentasvir) under FDA review for?
The application covered Adults and pediatric patients 3 years and older with acute or chronic hepatitis C virus (H. The FDA approved the application on June 11, 2025.
How did ENTA stock react to the FDA decision?
On the decision day ENTA moved +4.9%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.